Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis

Bleeding is a frequent complication of the management of patients with coronary artery disease (CAD), especially those presenting with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI), and of patients with atrial fibrillation (AF). Randomized trials have shown a risk of major bleeding of 1-8% at 30 days in ACS patients, and of 2-5% per year in patients with AF treated with oral anticoagulants (OACs). Observational studies suggest that bleeding risk is even higher. Major bleeding is associated with a subsequent increase in both short-And long-Term mortality. Evenminimal bleedingmay have prognostic importance because it frequently leads to disruption of antithrombotic therapy. Severalmechanisms have been put forward to explain the relationship between major bleeding and increased mortality (Figure 1). The overlap in risk factors for bleeding and ischaemic events means that patients who are more likely to suffer from bleeding complications of antithrombotic therapy also tend to be at higher risk of thrombotic events.Discontinuation of antithrombotic drugs may lead to an increased rate of thrombotic events due to the progressive recovery of platelet function and coagulation activity. In addition, bleeding may provoke prothrombotic responses beyond those related to discontinuation of antithrombotic drugs.Clearly, balancing the risks of further bleeding vs. potentially fatal thrombotic events is critical for decisions about if and when to restart antithrombotic therapy after bleeding.